ArticleCancer medicine2025
Second Cancer Incidence and Cause-Specific Mortality in Primary Gastrointestinal Non-Hodgkin Lymphoma Survivors: A Population-Based Cohort Study.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTherapeutic advances in primary gastrointestinal non-Hodgkin lymphoma (PGI-NHL) have improved patient prognosis but also raised concerns regarding long-term health outcomes. This study assesses patterns of second primary cancers (SPCs) and cause-specific mortality in PGI-NHL survivors.
methodsA total of 7556 six-month survivors of PGI-NHL diagnosed between 1975 and 2015 were identified from the SEER database. SPC risks were evaluated using overall and site-specific standardized incidence ratios (SIRs) and absolute excess risks (AERs) relative to the US general population. Cause-specific mortality was assessed through proportional death distribution, the Fine-Gray competing risk regression model, standardized mortality ratios (SMRs), and AERs.
resultsDuring 75,914 person-years of follow-up, 1245 patients developed 1412 SPCs (SIR = 1.20, 95% CI = 1.14-1.27). Significantly elevated SIRs were observed for solid tumors (SIR = 1.16, 95% CI = 1.10-1.23) and hematolymphoid malignancies (SIR = 1.82, 95% CI = 1.49-2.19). Survivors with over 20 years of follow-up faced increased risks of oral cavity and pharyngeal cancers (SIR = 2.76, 95% CI = 1.11-5.69), gastric cancer (SIR = 3.12, 95% CI = 1.15-6.80), pancreatic cancer (SIR = 2.40, 95% CI = 1.10-4.55), and leukemia (SIR = 2.57, 95% CI = 1.17-4.87). The risk of developing SPCs decreased with increasing age at PGI-NHL diagnosis. Patients receiving combined chemoradiotherapy exhibited the highest overall SPC risk (SIR = 1.32, 95% CI = 1.09-1.58), particularly for gastric cancer (SIR = 8.20, 95% CI = 4.59-13.53) and pancreatic cancer (SIR = 3.15, 95% CI = 1.44-5.98). A total of 4949 deaths occurred (SMR = 1.80, 95% CI = 1.75-1.85), with excess mortality persisting beyond two decades. The cumulative incidence of all-cause mortality was 28.9% at 5 years, 45.8% at 10 years, and 69.1% at 20 years post-diagnosis. Non-cancer causes posed a significant risk, with higher mortality from infections (SMR = 2.48, 95% CI = 2.22-2.76), chronic liver diseases (SMR = 1.72, 95% CI = 1.20-2.38), and benign/in situ neoplasms (SMR = 1.62, 95% CI = 1.05-2.38).
conclusionsPGI-NHL survivors face elevated long-term SPC risk, particularly after chemoradiotherapy and in younger patients. Excess risks for both SPCs and mortality persist beyond two decades, necessitating lifelong, risk-adapted survivorship care that includes cancer surveillance, infection prevention, and chronic comorbidity management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.